SCHEMBL7148669

SCHEMBL7148669

COc1ccc(Cc2c[nH]cn2)cc1NS(C)(=O)=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.41
KMT2A Q03164 3/20 0.40
MAPT P10636 1/20 0.40
BACE1 P56817 1/20 0.40
HTR1A P08908 1/20 0.40
HTR1D P28221 1/20 0.40
HTR1B P28222 1/20 0.40
ADRB3 P13945 2/20 0.39
TP53 P04637 1/20 0.38
NR3C1 P04150 1/20 0.37
ADRA2A P08913 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
ADRA1A P35348 2/20 0.37
ALDH1A1 P00352 3/20 0.37
MEN1 O00255 2/20 0.37
MAPK1 P28482 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
PTK2B Q14289 1/20 0.37
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7099288 0.84 MAPT (0.43) BRD4KMT2AMAPTBACE1NR3C1
SCHEMBL7102177 0.83 ADRA2A (0.56) ADRB3ADRA2AADRA2BADRA2CADRA1A
SCHEMBL14799028 0.75 HTR7 (0.50) BRD4KMT2AMAPTADRB3NR3C1
SCHEMBL7103193 0.75 PARP1 (0.48) BRD4KMT2ANR3C1ADRA2AADRA1A
SCHEMBL14452374 0.75 BRD4 (0.50) BRD4KMT2AMAPTADRB3TP53
SCHEMBL7105179 0.73 HPGD (0.39) BRD4MAPTTP53ADRA2AADRA1A
SCHEMBL5200788 0.73 HTR1B (0.51) HTR1DHTR1BADRA2AADRA2BADRA2C
SCHEMBL7098136 0.72 PSIP1 (0.43) MAPTADRA2AADRA1ASMN1; SMN2
SCHEMBL7097248 0.72 S100A9 (0.37) BRD4MAPTADRA2AADRA1ASMN1; SMN2
Hydrochloric Acid SCHEMBL5201882 0.72 HTR1B (0.50) KMT2AMAPTHTR1DHTR1BADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ABBOTT LABORATORIES 2003-04-17 US disclosed
US-6503935-B1 Treating urinary incontinence or retrograde ejaculation ABBOTT LABORATORIES 2003-01-07 US disclosed
EP-1102754-A1 IMIDAZOLES AND RELATED COMPOUNDS AS ALPHA-1A AGONISTS ABBOTT LABORATORIES (US) 2001-05-30 EP disclosed
WO-2000007997-A1 IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS ABBOTT LABORATORIES (US) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073850-A1 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use ADRA1D, ADRB1, ADRA1A BRD4 26/4885KMT2A 1672/4885MAPT 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.